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New practice guidelines for cervical cancer screening in
Switzerland recommend testing for the presence of DNA
from high-risk types of human papillomavirus (hrHPV)
as the primary screening test for all women 30 years and
older. However, the possibility that HPV testing might
not detect some cervical precancerous high-grade lesions
and cancers has raised questions about the performance
of HPV testing as a primary screening method for two
reasons. First, HPV-negative lesions (cervical intraepithe-
lial neoplasia grade 3 [CIN3], adenocarcinoma in situ or
invasive carcinoma [CIN3+]) have been found in studies
that analysed archived paraffin-embedded cervical tissue
[1] and in reviews of clinical records [2, 3]. Second, some
authors have reported that the combined use of HPV test-
ing with cytology (co-testing) identified CIN3+ in women
who had tested negative for HPV within 1 year before their
cervical biopsy [2]. Consequently, to maximise the detec-
tion of cervical cancer, co-testing has been recommended
as the primary screening method instead of HPV-testing
alone [4].
Recent data from Switzerland provide useful information
about HPV-negative CIN3+ lesions [5]. The CIN3+ plus
study was a cross-sectional study that provides baseline da-
ta for monitoring future HPV vaccine impact in Switzer-
land [5]. Ten pathology institutes from six cantons and
three language regions participated in the study. Each labo-
ratory conducted DNA extraction and HPV typing accord-
ing to their standard practice and was requested to partic-
ipate in the quality assurance system for HPV genotyping
designed by the World Health Organization (WHO) HPV
Laboratory Network [6, 7], to ensure comparable cover-
age of most important anogenital HPV genotypes by each
laboratory. Seven hundred and sixty-eight formaldehyde-
fixed, paraffin-embedded tissue specimens of histological-
ly confirmed CIN3+ cases were tested for any HPV type,
including the 12 genotypes that the International Agency
for Research on Cancer (IARC) recognises as causes of
cervical cancer (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58
and 59). Of these, 729 (95%) samples were hrHPV-posi-
tive and 39 samples were either hrHPV-negative (n = 20)
or not evaluable (n = 19) owing to inhibitors of the poly-
merase chain reaction (PCR) or lack of material. Confirma-
tory testing of 20 available samples (18 initially negative
samples and two initially nonevaluable samples) was per-
formed by the WHO Global Reference Laboratory, which
found 16 retested samples to be hrHPV positive. The final
results found: 97.0% (745/768) hrHPV positive, 2.3% (18/
768) nonevaluable and 0.7% (95% confidence interval [CI]
0.2–1.5%) (5/768) hrHPV negative. Only two of these
five negative samples could be subjected to confirmato-
ry testing. The hrHPV-positivity rate amongst all evalu-
able samples was therefore 99.3% (95% CI 98.5–99.8%,
745/750). The number of hrHPV-negative precancers and
cancers in the CIN3+ study was low but shows that a
small percentage of samples will have negative results
with hrHPV testing. The findings from retrospective stud-
ies and archival material cannot be directly extrapolated to
the performance of hrHPV testing in cervical samples in
screening populations because these studies include sam-
ples from both women who have presented with clinical
symptoms and asymptomatic women undergoing screen-
ing. Predictive values of hrHPV testing depend on the
prevalence of the disease, which is not comparable be-
tween these two populations of women.
In this article, we summarise the rationale for hrHPV test-
ing as the primary test for screening, explain potential rea-
sons for false-negative hrHPV test results in the presence
of CIN3+ lesions, describe true HPV-negative precancer
and cancer, and comment on the relevance of the debate
about co-testing versus hrHPV-only screening approaches
in Switzerland.
Primary hrHPV screening for cervical cancer
Randomised controlled trials and cohort studies have con-
sistently demonstrated the high sensitivity of clinically val-
idated hrHPV tests for the detection of clinical lesions. The
high negative predictive value allows longer screening in-
tervals than cytology alone [8]. Furthermore, randomised
controlled trials [9–15] showed that hrHPV testing detects
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more CIN3 lesions than cytology at the first screening
round and leads to an overall reduction in the incidence of
these lesions and of invasive cervical cancer in the follow-
ing years among the screened population. The protective
effect of HPV testing for CIN3 and invasive cancer was not
observed in the first 2.5 years after screening but increased
significantly thereafter.
The results of most randomised controlled trials also
showed that primary HPV screening applies only to
women from 30 years. In younger women, HPV testing has
a lower specificity for underlying precancer and cancer.
Based on these data and on cost-effectiveness modelling
analyses [16], several European countries (Italy, Denmark,
The Netherlands, UK, Estonia, Germany, Portugal, Spain,
Sweden, Turkey), as well as the USA, Australia, New
Zealand, and 10 other countries have now adopted or plan
to implement primary hrHPV testing as a stand-alone
screening modality without cytology.
Possible reasons for a negative hrHPV test re-
sult in a CIN3+ lesion
1. Reasons related to specimens. A false-negative hrHPV
test in a cervical sample could result from problems
with: the specimen, such as low hrHPV DNA copy
number owing to inadequate cellularity in the speci-
men or insufficient specimen collected from a clini-
cally overt cancer with necrosis, interfering substances
such as lubricants in the specimen, or suboptimal spec-
imen types. Tests for hrHPV were developed primarily
for use on fresh cytology specimens. When applied to
formaldehyde-fixed, paraffin-embedded tissues, tech-
nical artefacts resulting from poor DNA extraction and
quality and/or low viral load can result in negative test
results [17–19].
2. Reasons related to hrHPV tests. There are many differ-
ent hrHPV tests. A negative test result can occur if the
test does not detect a specific rare hrHPV type. Other
tests such as Hybrid Capture 2 [20] have limited ana-
lytic sensitivity. To minimise these deficiencies, clini-
cians are advised to use sufficiently sensitive and clini-
cally validated hrHPV tests for primary screening [21]
in qualified laboratories accredited by authorised ac-
creditation bodies and in compliance with international
standards. However, even very good HPV tests may
miss CIN3 lesions associated with hrHPV types in
1–3% of cases [22].
3. True hrHPV-negative CIN3 and cervical cancer. Al-
though hrHPV is a necessary causal factor in the path-
way to cervical cancers [23], hrHPV is not always de-
tected in tumour specimens from women diagnosed
with CIN3 or invasive cervical cancer. Nearly all CIN3
lesions are associated with hrHPV types, with a very
small proportion associated only with low risk HPV
types [24].
True primary cervical cancers not linked to HPV account
for a small portion of hrHPV-negative testing [25, 26].
They include endocervical adenocarcinomas of the gastric
type, minimal deviation adenocarcinomas, as well as clear
cell and mesonephric adenocarcinomas [27, 28]. A small
group of hrHPV-negative endocervical carcinomas have
features of endometrial adenocarcinomas. A recent study
systematically evaluated 777 cervical cancer tissues from
several US-based cancer registries and found carcinogenic
HPV in 91% of the cases. Nearly 60% of the HPV-negative
cases could not be distinguished histologically from en-
dometrial primary adenocarcinomas, suggesting that these
tumours may not be of cervical origin [29].
Histological findings of cervical adenocarcinoma with
hrHPV-negative testing should be verified using immunos-
taining for p16 and additional biomarkers to exclude an
origin from other sites.
There are limited data regarding the performance of the
Pap test for hrHPV-negative adenocarcinomas. Because
false negative Pap results are common with endocervical
adenocarcinomas [30], it is unclear how accurate cytology
is for the detection of these rare tumours.
Co-testing versus hrHPV-only primary screen-
ing
Prospective European randomised screening trials have
shown that adding cytology to hrHPV primary testing (co-
testing) offers minimal increased protection against the
subsequent development of cervical disease, at the expense
of a considerable loss in specificity (colposcopy is per-
formed if positive by either test), compared with hrHPV-
only primary screening [12, 14, 31–33]. Similar results
have been found in a large prospectively conducted US
FDA registration trial of primary hrHPV screening [15].
Another US study, which included approximately one mil-
lion women aged 30–65 years, demonstrated that co-test-
ing confers only a very slight marginal gain (0.003%) in re-
assurance (lower cancer risk) of safety against cancer over
5 years. Most of the reassurance provided by co-testing
was derived from the hrHPV test component. The study al-
so demonstrated that the 5-year reassurance after a nega-
tive co-test is approximately the same as the 4-year reas-
surance after a negative HPV test alone [14].
From a population management perspective, screening
modalities must be projected over the screening lifetime to
estimate what strategy is best for women in terms of ben-
efits, harms and costs. Primary screening with two tests,
especially in places like Switzerland where the prevalence
of disease in screened populations is very low, may lead
to over referral and overtreatment. Another consequence is
that two test results obtained simultaneously are difficult
to interpret resulting in significant algorithmic complexity
for the management of screened women [34]. Furthermore,
combined cytological and hrHPV screening is not cost-ef-
fective, since there is an increased cost without significant-
ly increasing sensitivity [35].
Conclusion
Testing for hrHPV DNA, like other cancer screening tests,
cannot detect all cases of prevalent or incipient cervical
cancer. Most missed cases are a small subset of adeno-
carcinomas that are not linked to HPV. The evidence base
demonstrated that a validated hrHPV test is sufficiently ac-
curate for clinical use and could reduce the complexities of
interpretation and management of co-test results as well as
resource expenditure inherent in screening with two tests.
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